Study of the effect of metformin on platelet aggregation in insulin-dependent diabetics

Decreased in vivo oxidative stress and decreased platelet activation following metformin treatment in newly diagnosed type 2 diabetic subjects

“…Tremoli and co-workers reported that addition of metformin to the chow in high-fat-fed rabbits reversed the enhanced platelet aggregability typical of this animal model [33]. An in vitro reduced adenosine diphosphate-induced platelet aggregation was also reported by Gin et al [34] in metformin-treated type 1 diabetic patients, while a later report by Nagi and Yudkin failed to demonstrate any significant changes in platelet aggregation following metformin treatment in type 2 diabetes [35]. In the present study we found that metformin, but not gliclazide treatment, was followed by decreased 11-dehydro-TXB 2 urinary excretion, a stable enzymatic metabolite of TXB 2 and a reliable parameter for the measurement of platelet activation in vivo [36,37].…”

The use of metformin in type 1 diabetes: a systematic review of efficacy

“…In total, 47 of these publications were judged to be relevant to metformin therapy in type 1 diabetes. Analysis of publications revealed: 17 were observational studies with no random allocation and/or no comparator group [18,22,[28][29][30][31][32][33][34][35][36][37][38][39][40][41][42]; 11 were reviews, letters or commentaries [43][44][45][46][47][48][49][50][51][52][53]; two did not contain any quantitative estimates of effects [54,55]; one concerned an outcome (erythrocyte binding of insulin) not judged relevant [56]; and four were abstracts of papers subsequently published [57][58][59][60]. Of the remaining 12 publications, one concerned insulin-requiring type 2 diabetes rather than type 1 diabetes (noted after translation) [61], and one covered a treatment period of fewer than 7 days [62].…”

“…• Observational; no random allocation and/or comparator groups (n=17) [18,22,[28][29][30][31][32][33][34][35][36][37][38][39][40][41][42] • Review, commentary, letter (n=11) [43][44][45][46][47][48][49][50][51][52][53] • Insufficient numerical data (n=2) [54,55] • No relevant outcome (n=1) [56] • Abstract of later paper (n=4) [57][58][59][60] • No evidence of type 1 diabetes after translation (n=1)…”

Novel therapeutic targets of metformin: metabolic syndrome and cardiovascular disease

“…Its effect on platelets is still poorly characterized, with studies suggesting decreased platelet aggregation [60], whereas others found no effect on platelet function [61].…”